|
Match
|
Document |
Document Title |
|
|
8173621 |
Nucleoside cyclicphosphates
Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or...
|
|
|
8173620 |
BHQ-caged nucleotide probes photolysable by two-photon excitation
The disclosure encompasses caged compounds such as caged nucleoside phosphoesters (caged nucleotides). In an embodiment, the caged nucleotides include compounds corresponding to those described by...
|
|
|
8153608 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an...
|
|
|
8133861 |
Systemic purine administration: modulating axonal outgrowth of central nervous system neurons
Methods for modulating the axonal outgrowth of central nervous system neurons are provided by means of internalized purine administration such as by intravenous, intraarterial, subcutaneous,...
|
|
|
8119614 |
Substitution derivatives of N6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
The invention concerns novel substitution derivatives of N6-benzyladenosine having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells. This...
|
|
|
8097595 |
Modulation of telomere length in telomerase positive cells and cancer therapy
Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention...
|
|
|
8093226 |
Cytostatic 7-deazapurine nucleosides
The invention provides compounds of formula I: wherein R1 and R2 have any of the values defined in the specification and salts thereof, as well as compositions comprising such compounds and...
|
|
|
8088752 |
Methods for metabolic modulation
Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine...
|
|
|
8076310 |
Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
Disclosed herein are novel phosphonate nucleosides and thiophosphonate nucleosides comprising a phosphonalkoxy-substituted or phosphonothioalkyl-substituted five-membered, saturated or unsaturated,...
|
|
|
8076311 |
Compositions and methods for modulating the immune system
The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides...
|
|
|
8067392 |
Compositions and methods for treatment of mitochondrial diseases
Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidien...
|
|
|
8063025 |
Nucleoside prodrugs and uses thereof
Compounds having the formula I or II wherein R1, R2, B, and V are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV...
|
|
|
8058258 |
Methods for cancer therapy and stem cell modulation
The present invention relates to a method of inducing apoptosis in a tumour cell as well as modulating pluripotency and/or self-renewing characteristics of a stem/progenitor cell. The method...
|
|
|
8058259 |
Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-pur
in-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions...
|
|
|
8048865 |
Method and pharmaceutical to treat spinal discs
Methods for reducing chronic pain caused by a disrupted spinal disc are described. In one method, a physiologically acceptable amount of an injectable is injected into the disc. The injectable is...
|
|
|
8034802 |
Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention...
|
|
|
8030293 |
Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders
The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such...
|
|
|
7994143 |
Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
The present invention relates to phosphonate, nucleoside phosphonate or nucleoside phosphate compounds, compositions containing them, processes for obtaining them, and their use in treating a...
|
|
|
7989430 |
Antibacterial agents
The invention provides compounds of formula (I) and salts thereof: R1-L-R2—B wherein R1, L, R2, and B have any of the values defined herein, as well as compositions comprising such compounds, and t...
|
|
|
7989431 |
2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.
|
|
|
7989188 |
Conjugates for cancer therapy and diagnosis
The present invention relates to conjugates of a drug and an amino acid or an amino acid derivative or analog, pharmaceutical compositions that include the conjugates and methods of use thereof. In...
|
|
|
7985737 |
Compositions and methods for the regulation of homocysteine levels within the body
Described herein is a method for reducing levels of the harmful metabolic waste product of S-adenosylmethionine (SAMe), homocysteine, and provide vitamin and other nutritional co-factors that...
|
|
|
7985740 |
Purine derivatives as agonists of the adenosine A2A receptor
The invention provides novel compounds which are agonists of the adenosine 2A receptor along with pharmaceutical compositions thereof, and methods of administering such compounds.
|
|
|
7977343 |
Adenine derivatives
Novel adenine derivatives of the formula (I), in which R1, R2, R3, X and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the...
|
|
|
7977320 |
Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
The present invention provides compositions and methods for increasing the amount of active Syk protein kinase and or SHP-1 protein phosphatase in a cell. The compositions and methods are useful...
|
|
|
7947709 |
Non-nucleoside reverse transcriptase inhibitors
Compounds of formula I, wherein R1, R2, R3, X and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and...
|
|
|
7943593 |
Compositions comprising inhibitors of IMPDH enzyme
The present invention relates to compositions comprising an apoptosis inducing anti-cancer agent and an IMPDH inhibitor. This invention also relates to methods for inducing apoptosis and for...
|
|
|
7935680 |
Methods for modulating the axonal growth of central nervous system neurons
Methods for modulating the axonal outgrowth of central nervous system neurons are provided. Methods for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g.,...
|
|
|
7928085 |
P-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazole[4,5-d]pyrimidine-2-one and methods for preparation
The present disclosure relates to p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-beta-D-ribofuranosyl)-3H
-thiazolo[4,5-d]pyrimidin-2-one and to its use in treating conditions suc...
|
|
|
7915232 |
4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication
The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof which...
|
|
|
7875595 |
2-polycyclic propynyl adenosine analogs having A2A agonist activity
The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.
|
|
|
7867983 |
Methods to protect skeletal muscle against injury
Disclosed herein are compositions and methods for the treatment of skeletal muscle and/or the protection of skeletal muscle against injury. The adenosine A3 receptor has been identified as a new...
|
|
|
7863250 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an...
|
|
|
7851453 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an...
|
|
|
7851456 |
P2Y6 receptor agonists for treating lung diseases
This invention is directed to a method of enhancing or facilitating the clearance of the lung mucus secretions in a subject. This invention is also directed to a method of facilitating the...
|
|
|
7846912 |
Deuterium-enriched nelarabine
The present application describes deuterium-enriched nelarabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
7842672 |
Phosphonate inhibitors of HCV
A compound of Formula I, Formula II, Formula III, or Formula IV: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, therapeutic compositions containing such compounds, and...
|
|
|
7838508 |
4′-thio-L-xyloy furanosyl nucleosides, precursors thereof, preparation and use thereof
Compounds represented by the formula 1: A is selected from the group consisting of wherein each R individually is H or acyl, Y is X, N3, NH2, monoalkylamino, or dialkylamino; Z is O or S; andX is...
|
|
|
7825096 |
O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
Disclosed are prodrugs of inactivators of O6-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the β-glucuronidase enzyme, which is either administered to the patient or ...
|
|
|
7820636 |
Sugar intake promoters
An object of the invention is to provide a substance that activates saccharide uptake in epidermal cells and is thus expected to be effective in promoting skin cell neogenesis and metabolism. The...
|
|
|
7820637 |
Use of 5′-methylthioadenosine (MTA) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection
5′-methylthioadenosine (MTA), its pharmaceutically acceptable salts and/or prodrugs may be used in the prevention and/or treatment of autoimmune diseases, such as, for example, Multiple Sclerosis (...
|
|
|
7816333 |
Oligonucleotide analogues and methods utilizing the same
A method for the prevention or treatment in a mammal of a disease preventable or treatable by the pharmacologically useful antisense or antigene activity of an oligonucleotide analogue or a...
|
|
|
7812000 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods...
|
|
|
7795236 |
Purine nucleoside derivative modified in 8-position and medical use thereof
The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside...
|
|
|
7792576 |
Method of treatment for central nervous system injury
Injuries to the central nervous system, particularly spinal cord injuries, are treated by administering a purine nucleoside or analog to the patient and, optionally, electrically stimulating the...
|
|
|
7781432 |
Analogs of nitrobenzylthioinosine
Analogs or derivatives of nitrobenzylthioinosine corresponding to formula I: in which R represents an unsubstituted or mono- or polysubstituted phenyl, benzyl or heteroaryl group or a phenyl group...
|
|
|
7772206 |
Methods and compositions for the treatment of autoimmune disorders using clofarabine
This invention relates to methods of treating or preventing an autoimmune disorder comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate, clathrate,...
|
|
|
7772198 |
CFTR channel modulators
The invention concerns pharmaceutical formulas designed for the treatment of diseases related to CFTR channel dysfunction, such as cystic fibrosis, asthma or diarrhoea. These formulas contain a...
|
|
|
7749975 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods...
|
|
|
7749980 |
Non-nucleotide compositions and method for treating pain
The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor...
|